November 2003
This chart may not adequately reflect the percentages of side effects in women due to the limited number of women in many studies of these drugs.
The colors underneath each drug heading below indicate the rough percentage of people reporting each side effect for each drug. See key at the bottom of each section.
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
APV = Amprenavir; ATV = Atazanavir; fosAPV = Fosamprenavir; IDV = Indinavir;
LPV = Lopinavir + RTV; NFV = Nelfinavir; RTV = Ritonavir;
SQV(hgc) = Saquinavir hard gel capsule; SQV(sgc) = Saquinavir soft gel capsule
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
DLV = Delavirdine; EFV = Efavirenz; NVP = Nevirapine
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
ABV=Abacavir; Combivir = AZT + 3TC; Trizivir = AZT + 3TC + ABV
FTC=Emtricitabine; TNV = Tenofovir
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
T20 = Enfuvirtide
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
Other Side Effect WarningsAll Anti-HIV DrugsChanges in body fat distribution, called lipodystrophy, have been associated both with HIV infection and anti-HIV therapy. A warning about lipodystrophy is now included in the label information for all anti-HIV drugs. All Nucleoside AnalogsA build-up of lactic acid in the body (lactic acidosis) and severe liver enlargement (hepatomegaly) with fatty liver (steatosis), including fatal cases, have been reported with using NRTIs alone or in combination. Fatal lactic acidosis has been reported in pregnant women who took d4T (stavudine, Zerit) and ddI (didanosine, Videx) with other anti-HIV drugs. The combination of d4T and ddI should be used with caution during pregnancy. AZTAZT (zidovudine, Retrovir) has been associated with low neutrophil counts (neutropenia) and severe reductions in red blood cells (anemia), particularly in patients with advanced HIV disease. Prolonged use of AZT has been associated with muscle weakness (myopathy). AbacavirFatal hypersensitivity reactions have occurred in up to 8.5% of people taking abacavir (Ziagen). People with fever, skin rash, fatigue, nausea, vomiting, diarrhea, abdominal pain, and/or respiratory symptoms are advised to call their doctor immediately and stop using abacavir if directed, as soon as a hypersensitivity reaction is suspected. Once abacavir treatment is stopped, it should be permanently discontinued as a more severe reaction may recur within hours if it is restarted and may include life-threatening symptoms and death. d4T/ddIFatal and non-fatal inflammation in the pancreas (pancreatitis) has occurred with the combination of d4T and ddI. Neither d4T nor ddI should be used in people with suspected or confirmed pancreatitis. EnfuvirtideNearly 100% of people using enfuvirtide (T20, Fuzeon) will have injection site reactions including redness, inflammation, pain and hardening of the skin. |
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |